A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 421,708 shares of CGEM stock, worth $7.25 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
421,708
Previous 321,100 31.33%
Holding current value
$7.25 Million
Previous $5.47 Million 34.39%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$15.63 - $29.35 $1.57 Million - $2.95 Million
100,608 Added 31.33%
421,708 $7.35 Million
Q1 2024

May 13, 2024

BUY
$10.17 - $19.02 $579,812 - $1.08 Million
57,012 Added 21.59%
321,100 $5.47 Million
Q4 2023

Feb 13, 2024

BUY
$7.89 - $10.23 $326,551 - $423,399
41,388 Added 18.58%
264,088 $2.69 Million
Q3 2023

Nov 14, 2023

SELL
$9.05 - $11.72 $207,245 - $268,388
-22,900 Reduced 9.32%
222,700 $2.02 Million
Q2 2023

Aug 11, 2023

BUY
$8.8 - $13.4 $56,320 - $85,760
6,400 Added 2.68%
245,600 $2.64 Million
Q1 2023

May 12, 2023

SELL
$10.2 - $11.91 $698,700 - $815,835
-68,500 Reduced 22.26%
239,200 $2.45 Million
Q4 2022

Feb 13, 2023

BUY
$9.72 - $13.62 $53,508 - $74,978
5,505 Added 1.82%
307,700 $3.25 Million
Q3 2022

Nov 14, 2022

BUY
$11.82 - $15.42 $101,592 - $132,534
8,595 Added 2.93%
302,195 $3.87 Million
Q2 2022

Aug 12, 2022

BUY
$7.31 - $13.55 $2.15 Million - $3.98 Million
293,600 New
293,600 $3.76 Million
Q1 2022

May 13, 2022

SELL
$10.47 - $16.75 $278,502 - $445,550
-26,600 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$15.36 - $25.0 $408,576 - $665,000
26,600 New
26,600 $410,000
Q3 2021

Nov 12, 2021

SELL
$22.56 - $29.68 $586,153 - $771,145
-25,982 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$24.96 - $41.25 $648,510 - $1.07 Million
25,982 New
25,982 $669,000

Others Institutions Holding CGEM

About Cullinan Oncology, Inc.


  • Ticker CGEM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,612,200
  • Market Cap $784M
  • Description
  • Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...
More about CGEM
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.